IP situation: posting my earlier reply from Cafepharma to another overly optimistic plecanatide IP spin post - enjoy.
Originally Posted by Anonymous
IP agreement with IRWD blocks competition. Despite the company’s patent–license agreement with Ironwood, there’s still some investor belief that an intellectual property overhang exists on the stock, thus, the company’s plecanatide patents are worth touching on. The patent deal with IRWD, announced in September of 2012, actually blocks other companies from entering into the GC-C agonist segment and competing in the key IBS-C or CIC indications, or any other inflammatory GI diseases or cancers with the technology. As a result, for large companies hoping to enter this drug class, SGYP is the only asset available for acquisition or partnering and this is why the company is likely to be on analyst take-out lists this year. Synergy has two patents covering the composition of plecanatide – one is a broad patent covering several analogues of uroquanylin (the parent structure of plecanatide), and the other is a patent covering the specific structure of plecanatide itself. These patents, with Hatch Waxman exclusivity, are expected to expire in 2025, and the company continues to evolve its patent estate.
Plecanatide is an analogue of uroquanylin, with one amino acid different from the active form of uroquanylin. The replacement of aspartic acid with glutamic acid fixes the structure in a rigid (partially closed) state, which was designed to act in the intestine and is more stable and more potent than uroquanylin. This novel peptide structure was also designed for optimum low-cost manufacturing.
Ironwood obtained a patent on the use of plecanatide in IBS-C and CIC after multiple rejections by the U.S. Patent and Trade Office (PTO), but of course, Ironwood cannot sell the product in these indications because plecanatide (its composition of matter) is owned by Synergy. Synergy never applied for this “use” patent, as i
Had to add a 3 months to each original projection. He said trial results in Q2, but in reality, it will be Q3
so it seems..
According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, analyst Joseph Pantginis currently has a one-year average return of -6.1% and a 33% success rate. Pantginis has a 6.9% average loss recommending CRIS, and he is ranked #3050 out of 3123 analysts.
Poor Joe: he is ranked #3050 out of 3123 analysts.
so it seems...
Down to $3.86. Every short in the world should cover today and book their huge gains.
So it seems
you want to hit a home run.. I would sell all my SGYP right now and invest in cancer companies.
So it seems to our team.. LA is a great place to have a business!
Nothing left here to short. Much better opportunities. We squeezed enough out of this one..
We rode this from $6.40 to $3.81 and we are done. We did good..
Wash, rinse, repeat.. Middle of 2016 is a long time in the biotech world.